Citation

Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Mölgaard J, Holme I, Walldius G. 1995. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: a Probucol Quantitative Regression Swedish Trial (PCRST) Report. Arteriosclerosis, Thrombosis, and Vascular Biology 15(8):1049-1056.